SCHEMBL503210

SCHEMBL503210

Cc1ccc(SC[C@H](N)C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 14/20 0.59
HPGD P15428 2/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
USP2 O75604 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
GRIK1 P39086 1/20 0.43
GRIK2 Q13002 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668576 1.00 KIF11 (0.59) KIF11HPGDALDH1A1LMNAMAPT
SCHEMBL29191726 0.84 KIF11 (0.43) KIF11
SCHEMBL9065200 0.84 KIF11 (0.43) KIF11
Cystine SCHEMBL27941982 0.83 KIF11 (0.65) KIF11GRIK1GRIK2
SCHEMBL6223407 0.83 MAOA (0.57) KIF11
SCHEMBL342512 0.83 MAOA (0.57) KIF11
SCHEMBL1157625 0.83 MAOA (0.57) KIF11
SCHEMBL11869200 0.82 KIF11 (0.55) KIF11ALDH1A1LMNAMAPTKMT2A
SCHEMBL11570330 0.82 KIF11 (0.55) KIF11ALDH1A1LMNAMAPTKMT2A
Hydrochloric Acid SCHEMBL3319856 0.81 MAOA (0.55) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11274126-B2 pH-sensitive cyclic peptides UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) 2022-03-15 US claimed
CN-105264064-B O-phosphoserine export proteins and methods of producing O-phosphoserine using the same CJ第一制糖株式会社 2020-08-18 CN claimed
EP-3348567-B1 NOVEL O-PHOSPHOSERINE EFFLUX PROTEIN VARIANT AND METHOD FOR PRODUCING O-PHOSPHOSERINE, CYSTEINE AND DERIVATIVE THEREOF USING SAME CJ CHEILJEDANG CORP (KR) 2020-08-05 EP claimed
EP-3181685-B1 O-PHOSPHOSERINE PRODUCING MICROORGANISM AND METHOD FOR PRODUCING O-PHOSPHOSERINE OR L-CYSTEINE USING SAME CJ CHEILJEDANG CORP (KR) 2019-08-14 EP claimed
EP-3432908-A1 pH-SENSITIVE PEPTIDES Rhode Island Council on Postsecondary Education (US) 2019-01-30 EP claimed
WO-2017165452-A1 pH-SENSITIVE PEPTIDES RHODE ISLAND COUNCIL ON POSTSECONDARY EDUCATION (US) 2017-09-28 WO claimed
US-12529082-B2 O-phosphoserine export protein variant and method for producing O-phosphoserine, cysteine, and derivatives thereof using the same CJ CHEILJEDANG CORPORATION (KR) 2026-01-20 US disclosed
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME NEW YORK UNIVERSITY (US) 2026-01-01 US disclosed
US-20250376493-A1 NOVEL YhhS VARIANT AND METHOD FOR PRODUCING O-PHOSPHOSERINE, CYSTEINE, AND DERIVATE OF CYSTEINE USING SAME CJ CHEILJEDANG CORPORATION (KR) 2025-12-11 US disclosed
US-12371461-B2 Nemo coiled coil mimics and methods of using same NEW YORK UNIVERSITY (US) 2025-07-29 US disclosed
EP-3303367-B1 STABILIZED MINIMAL COILED-COIL MIMETICS UNIV NEW YORK (US) 2025-06-18 EP disclosed
US-12290575-B2 Fluorescent compound comprising a fluorophore conjugated to a pH-triggered polypeptide UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) 2025-05-06 US disclosed
US-20250075221-A1 O-PHOSPHOSERINE-PRODUCING MICROORGANISM AND METHOD FOR PRODUCING O-PHOSPHOSERINE OR L-CYSTEINE USING THE SAME CJ CHEILJEDANG CORPORATION (KR) 2025-03-06 US disclosed
WO-2012166533-A1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS ALLERGAN, INC. (US) 2012-12-06 WO disclosed
WO-2012166544-A1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ALLERGAN, INC. (US) 2012-12-06 WO disclosed
US-20120302621-A1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS ALLERGAN, INC. 2012-11-29 US disclosed
US-20120028362-A1 2-QUINOXALINOL SALEN COMPOUNDS AND USES THEREOF AUBURN UNIVERSITY (US) 2012-02-02 US disclosed
EP-2139461-A2 AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER Recepticon Aps (DK) 2010-01-06 EP disclosed
US-20090286968-A1 2-Quinoxalinol Salen Compounds and Uses Thereof AUBURN UNIVERSITY (US) 2009-11-19 US disclosed
WO-2008113364-A2 AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER RECEPTICON APS (DK) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274126-B2 pH-sensitive cyclic peptides VIP, PHLPP1, PHLPP2 KIF11 4026/4885HPGD 1517/4885ALDH1A1 4877/4885
US-12371461-B2 Nemo coiled coil mimics and methods of using same COIL, CALCOCO2, NCAPH KIF11 1551/4885HPGD 3153/4885ALDH1A1 3890/4885
US-20090286968-A1 2-Quinoxalinol Salen Compounds and Uses Thereof NQO1, NQO2, SQOR KIF11 3663/4885HPGD 143/4885ALDH1A1 1265/4885
US-20120028362-A1 2-QUINOXALINOL SALEN COMPOUNDS AND USES THEREOF NQO1, NQO2, SQOR KIF11 3663/4885HPGD 143/4885ALDH1A1 1265/4885
US-12290575-B2 Fluorescent compound comprising a fluorophore conjugated to a pH-triggered polypeptide NPPA, LNPEP, VIP KIF11 1920/4885HPGD 2457/4885ALDH1A1 2449/4885
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME DDX21, PHAX, RBX1 KIF11 4251/4885HPGD 3189/4885ALDH1A1 4748/4885
US-12529082-B2 O-phosphoserine export protein variant and method for producing O-phosphoserine, cysteine, and derivatives thereof using the same PSPH, PHAX, MARS1 KIF11 716/4885HPGD 3051/4885ALDH1A1 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.